IPP Bureau
Functional Gut Clinic launches UK’s first boutique GI clinical trials division
By IPP Bureau - January 23, 2026
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
By IPP Bureau - January 23, 2026
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'
By IPP Bureau - January 23, 2026
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
G Square acquires majority stake in Finnish surgical solutions leader Serres
By IPP Bureau - January 23, 2026
Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
By IPP Bureau - January 23, 2026
The partnership initially will focus on cardiovascular and kidney diseases
Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
By IPP Bureau - January 23, 2026
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
CORONA Remedies secures EAEU-GMP certification
By IPP Bureau - January 23, 2026
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits
By IPP Bureau - January 23, 2026
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
By IPP Bureau - January 23, 2026
This marks the second indication for which gumokimab has gained NDA review acceptance
EMA hits record high in vet medicine nods for second year running
By IPP Bureau - January 23, 2026
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
iRegene’s Parkinson’s therapy gains FDA designation
By IPP Bureau - January 21, 2026
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
AstraZeneca gains full global rights to AbelZeta’s CAR-T therapy in $630M deal
By IPP Bureau - January 21, 2026
Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
By IPP Bureau - January 21, 2026
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing
By IPP Bureau - January 21, 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
